CureVac (NASDAQ:CVAC - Get Free Report) fell 3.7% during mid-day trading on Wednesday . The stock traded as low as $4.00 and last traded at $3.99. 98,708 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,485,596 shares. The stock had previously closed at $4.14.
The firm has a market cap of $891.71 million, a price-to-earnings ratio of 7.23 and a beta of 2.50. The stock has a 50-day moving average of $3.26 and a 200-day moving average of $3.18. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05.
Hedge funds have recently bought and sold shares of the company. Barclays PLC acquired a new position in CureVac during the 3rd quarter worth $67,000. Public Employees Retirement System of Ohio acquired a new stake in CureVac in the third quarter worth about $91,000. Jane Street Group LLC grew its position in CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock valued at $235,000 after buying an additional 55,867 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in CureVac during the 3rd quarter valued at about $35,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of CureVac by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company's stock worth $127,000 after buying an additional 16,792 shares in the last quarter. 17.26% of the stock is currently owned by institutional investors.
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.